Pharmacological profile of ZD1611, a novel, orally active endothelin ET(A) receptor antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 3, 1999, Pages 1085-1091

  Wilson, Campbell ^a   Hunt, Sarah Jane ^a   Tang, Eric ^a   Wright, Nicola ^a   Kelly, Elizabeth ^a   Palmer, Sharon ^a   Heys, Christine ^a   Mellor, Susan ^a   James, Roger ^a   Bialecki, Russell ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 [3 (3 METHOXY 5 METHYL 2 PYRAZINYLSULFAMOYL) 2 PYRIDYL]PHENYL] 2,2 DIMETHYLPROPIONIC ACID; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR AGONIST; IODINE 125; N ACETYLENDOTHELIN 1 [6-21][11,15 ALANINE]; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG POTENCY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; LIGAND BINDING; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ADMINISTRATION, ORAL; ANIMALS; AORTA; BINDING, COMPETITIVE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; ENDOTHELINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; KINETICS; MALE; MICE; PEPTIDE FRAGMENTS; PYRAZINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 0032774208     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Arai H, Aramori, I, Hiroaki O and Nakanishi S (1990) Cloning and expression of a cDNA encoding an endothelin receptor. Nature (Lond) 348:730-732.
2. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 14:48-58.
3. Bialecki RA and Tulenko TN (1989) Excess membrane cholesterol alters calcium channels in arterial smooth muscle. Am J Physiol 257:C306-C314.
4. Clozel M, Breu V, Gray G, Kalina B, Loffler B-M, Burri K, Cassal J-M, Hirth G, Muller M, Neidhart W and Ramuz H (1994) Pharmacological characterization of Bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 270:228-235.
5. A subtype. Br J Pharmacol 114:1110-1116.
6. Devadason PSS and Henry PJ (1997) Comparison of the contractile effects and binding kinetics of endothelin-1 and sarafotoxin S6b in rat isolated renal artery. Br J Pharmacol 121:253-263.
7. B receptors in rats. Biochem Biophys Res Commun 199:1461-1465.
8. Fukuroda T, Noguchi K, Tsuchida S, Nishikibe M, Ikemoto F, Okada K and Yano M (1990) Inhibition of biological actions of big ET-1 by phosphoramidon. Biochem Biophys Res Commun 172:390-395.
9. Gasic S, Wagner OF, Vierhapper H, Nowotny P and Waldhausl W (1992) Regional hemodynamic effects and clearance of endothelin-1 in humans: Renal and peripheral tissues may contribute to the overall disposal of the peptide. J Cardiovasc Pharmacol 19:176-180.
10. Godfraind T (1993) Evidence for heterogeneity of endothelin receptor distribution in human coronary artery. Br J Pharmacol 110:1201-1205.
11. Hemsen A, Larsson O and Lundberg JM (1991) Characteristics of endothelin A and B binding sites and their vascular effects in pig peripheral tissues. Eur J Pharmacol Mol Pharmacol Sect 208:313-322.
12. Hirata Y, Yoshimi H, Takata S, Watanabe TX, Kumagai S, Nakajima K and Sakakibara S (1988) Cellular mechanism of action by a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells. Biochem Biophys Res Commun 154:868-875.
13. Ihara M, Saeki T, Funabashi K, Nakamichi K, Yano M, Fukuroda T, Miyaji M, Nishikibe M and Ikemoto F (1991) Two endothelin receptor subtypes in porcine arteries. J Cardiovasc Pharmacol 17 (Suppl 7):S119-S121.
14. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K and Masaki T (1989) The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 86:2863-2867.
15. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM and Burnett JC (1991) Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 325:997-1001.
16. Love MP and McMurray JJ (1997) Endothelin in heart failure - A promising therapeutic target? Heart 77:93-94.
17. A receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol 115:191-197.
18. Marsault R, Feolde E and Frelin C (1993) Receptor externalisation determines sustained contractile responses to endothelin-1 in the rat aorta. Am J Physiol 284:C687-C693.
19. Masaki T (1995) Possible role of endothelin in endothelial regulation of vascular tone. Annu Rev Pharmacol Toxicol 85:235-265.
20. McMurdo L, Corder R, Thiemermann C and Vane JR (1993) Incomplete inhibition of the pressor effects of endothelin-1 and related peptides in anaesthetised rat with BQ123 provides evidence for more than one vasoconstrictor receptor. Br J Pharmacol 108:557-561.
21. Miyauchi T, Yanagisawa M and Tomizawa T (1989) Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet 2:53-54.
22. Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, Yans M, Yamaguchi I, Sugishita Y and Goto K (1993) Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 73:887-897.
23. Moreland S, McMullen DM, Delaney CL, Lee VG and Hunt JT (1992) Venous smooth muscle contains vasoconstrictor ETB-like receptors. Biochem Biophys Res Commun 184:100-106.
24. Needham M, Gooding C, Hudson K, Antoniou M, Grosveld F and Hollis M (1992) LCR/MEL: A versatile system for high level expression of heterologous proteins in erythroid cells. Nucleic Acids Res 20:997-1003.
25. Ohlstein E, Nambi P, Lago A, Hay DWP, Beck G, Fong K-L, Eddy P, Smith P, Ellens H and Elliott JD (1996) Nonpeptide endothelin receptor antagonists. VI. Pharmacological characterization of SB217242, a potent and highly bioavailable endothelin receptor antagonist. J Pharmacol Exp Ther 276:609-615.
26. Ohlstein EH and Douglas SA (1993) Endothelin-1 modulates vascular smooth muscle structure and vasomotion: Implications in cardiovascular pathology. Drug Dev Res 29:108-128.
27. Ohlstein EL, Beck G, Douglas SA, Nambi P, Lago MA, Gleason JG, Ruffolo RR, Feuerstein G and Elliott JD (1994) Nonpeptide endothelin antagonists. II. Pharmacological characterization of SB 209670. J Pharmacol Exp Ther 271:762-768.
28. Opgenorth TJ, Adler AL, Calzadilla SV, Chiou WJ, Dayton BD, Dixon DB, Gehrke LJ, Hernandez L, Magnuson SR, Marsh KC, Novosad EI, Von Gerldern TW, Wessale JL, Winn M and Wu-Wong JR (1996) Pharmacological characterization of A-127722: An orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 276:473-481.
29. Panek RL, Major TC, Hingorani GP, Doherty AM, Taylor DG and Rapundalo ST (1992) Endothelin and structurally related analogues distinguish between endothelin receptor subtypes. Biochem Biophys Res Commun 183:566-571.
30. Patel TR, Galbraith S, Graham DI, Hallak H, Doherty AM and McCulloch J (1996) Endothelin receptor antagonist increases cerebral perfusion and reduces ischaemic damage in feline focal cerebral ischaemia. J Cereb Blood Flow Metab 16:950-958.
31. Reynolds EE, Keiser JA, Haleen SJ, Walker DM, Olszewski B, Schroeder RL, Taylor DG, HwangO, Welch KM, Flynn MA, Thompson DM, Edmunds JJ, Berryman KA, Plummer M, Cheng X-M, Patt WD and Doherty AM (1995) Pharmacological characterization of PD156707, an orally active ETA receptor antagonist. J Pharmacol Exp Ther 273:1410-1417.
32. Sakurai T, Yanagisawa M and Masaki T (1992) Molecular characterization of endothelin receptors. Trends Pharmacol Sci 13:103-108.
33. Sakurai T, Yanagisawa M, Yakuwa Y, Miyazaki H, Kimura S, Goto K and Masaki T (1990) Cloning of cDNA encoding a non-peptide-selective subtype of endothelin receptor. Nature (Lond) 348:732-735.
34. A receptor antagonist. J Pharmacol Exp Ther 264:1040-1046.
35. S tewart DJ, Levy RD, Cernacek P and Langleben D (1991) Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease. Intern Med 114:464-469.
36. Stockenhuber F, Gottsauner-Wolf M, Marosi L, Liebisch B, Kurz RW (1992) Plasma levels of endothelin in chrome renal failure and after renal transplantation: Impact on hypertension and cyclosporin A-associated nephrotoxicity. Clin Sci 82:255-258.
37. Suzuki R, Masaoka H, Hirata Y, Marumo F, Isotani E and Hirakawa K (1992) The role of endothelin-1 in the origin of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 77:96-100.
38. Takimoto M, Inui T, Okada T and Urade Y (1993) Contraction of smooth muscle by activation of endothelin receptors on autonomie neurons. FEBS Lett 324:277-282.
39. Tomita K, Ujiie K, Nakanishi T, Tomura S, Matsuda O, Ando K, Shichiri M, Hirata Y and Marumo F (1989) Plasma endothelin levels in patients with acute renal failure. N Engl J Med 321:1127.
40. Warner TD, Mitchell JA, de Nucci G and Vane JR (1989) Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovasc Pharmacol 13 (Suppl 6):S85-S88.
41. Webb ML, Bird JE, Liu ECK, Rose PM, Serafino R, Stein PD and Moreland S (1995) BMS-182874 is a selective, nonpeptide endothelin ETA receptor antagonist. J Pharmacol Exp Ther 272:1124-1134.
42. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki G and Masaki T (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (Lond) 332:411-415.